A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age
Latest Information Update: 15 Jul 2020
At a glance
- Drugs JNJ 64400141 (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 15 Jul 2020 This trial has been completed in Sweden.
- 09 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2019 Planned End Date changed from 14 May 2021 to 31 Oct 2021.